KAVANAGH, JJEDWARDS, CLFREEDMAN, RSFINNEGAN, MBBALAT, OTRESUKOSOL, DBURK, K2024-08-042024-08-0419950090-82581095-6859https://doi.org/10.1006/gyno.1995.1191https://hdl.handle.net/11616/93011Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy, A fundamental difficulty is the development of tumor resistance to platinum compounds, Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines, Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m(2) but was later reduced to 40 mg/m(2) because of excessive thrombocytopenia, Nine patients required red cell transfusions during therapy, Cycles were repeated every 21-35 days (median cycle length 28 days), No objective responses were observed, Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer. (C) 1995 Academic Press, Inc.eninfo:eu-repo/semantics/closedAccessCarcinomaArticle581106109778987410.1006/gyno.1995.11912-s2.0-0029075747Q1WOS:A1995RG49700018N/A